Show simple item record

dc.contributor.authorThatcher, Nick
dc.contributor.authorPalmer, Michael K
dc.contributor.authorGasiunas, Nijole
dc.contributor.authorCrowther, Derek
dc.date.accessioned2010-07-21T14:56:32Z
dc.date.available2010-07-21T14:56:32Z
dc.date.issued1977-12
dc.identifier.citationLymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma. 1977, 36 (6):751-62 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid597473
dc.identifier.urihttp://hdl.handle.net/10541/108091
dc.description.abstractThirty-eight patients with metastatic melanoma were investigated for lymphocyte function immediately prior to chemo-immunotherapy. The pre-treatment immune tests were compared with normal control values and with response to therapy. The "non-responder" group (but not "responder") had significantly reduced values for lymphocyte, null-cell and E-rosette-cell counts compared with controls. Lymphocytoxicity ( using a Chang target cell) showed the same pattern, with depression of direct and K-cell cytotoxic capacity in non-responders compared with controls. Eight patients were studied sequentially whilst on treatment, and demonstrated considerable change (not statistically significant) in lymphocytotoxicity, an untreated "control" patient showed little variation. "Recall"-antigen skin testing showed no statistically significant difference between the patient groups. The data indicate that "non-T-cell activity" may be associated with response to chemo-immunotherapy.
dc.language.isoenen
dc.subjectCancer Metastasisen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshBCG Vaccine
dc.subject.meshCytotoxicity, Immunologic
dc.subject.meshDacarbazine
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLeukocyte Count
dc.subject.meshLymphocytes
dc.subject.meshMale
dc.subject.meshMelanoma
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Metastasis
dc.subject.meshRosette Formation
dc.titleLymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Medical Oncology of Manchester University.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractThirty-eight patients with metastatic melanoma were investigated for lymphocyte function immediately prior to chemo-immunotherapy. The pre-treatment immune tests were compared with normal control values and with response to therapy. The "non-responder" group (but not "responder") had significantly reduced values for lymphocyte, null-cell and E-rosette-cell counts compared with controls. Lymphocytoxicity ( using a Chang target cell) showed the same pattern, with depression of direct and K-cell cytotoxic capacity in non-responders compared with controls. Eight patients were studied sequentially whilst on treatment, and demonstrated considerable change (not statistically significant) in lymphocytotoxicity, an untreated "control" patient showed little variation. "Recall"-antigen skin testing showed no statistically significant difference between the patient groups. The data indicate that "non-T-cell activity" may be associated with response to chemo-immunotherapy.


This item appears in the following Collection(s)

Show simple item record